Filter
1971
Filtered Results: 1971
Text search:
drug
regimens
Featured
Recommendations
205
New Publications
533
Language
Document type
No document type
1293
Guidelines
274
Studies & Reports
233
Manuals
58
Strategic & Response Plan
34
Fact sheets
34
Training Material
23
Situation Updates
7
Infographics
7
Resource Platforms
4
Brochures
2
Online Courses
2
Countries / Regions
India
121
South Africa
63
Kenya
52
Ethiopia
49
Global
47
Tanzania
45
Western and Central Europe
42
Uganda
37
Nigeria
35
Zambia
34
Nepal
31
Eastern Europe
31
Rwanda
28
Africa
28
Malawi
24
Ghana
22
Liberia
21
Ukraine
21
Latin America and the Carribbean
21
Philippines
18
Bangladesh
18
Namibia
18
Myanmar / Burma
18
Asia
17
Zimbabwe
16
Cambodia
15
Sierra Leone
12
Mozambique
12
Russia
12
Indonesia
11
Lesotho
11
South–East Asia Region
11
Botswana
10
Eswatini/ Swaziland
8
Senegal
7
Cameroon
7
Thailand
7
Colombia
7
Congo, Democratic Republic of
6
Brazil
6
Haiti
5
East and Southern Africa
5
West and Central Africa
5
Albania
5
Georgia
5
USA
4
Pakistan
4
Syria
4
Argentina
4
Venezuela
4
Tajikistan
4
South Sudan
3
Germany
3
China
3
Benin
3
Western Pacific Region
3
Bhutan
3
Estonia
3
Vietnam
3
Jamaica
3
Burkina Faso
2
Somalia
2
Iraq
2
Afghanistan
2
Sudan
2
Sri Lanka
2
Middle East and North Africa
2
Eastern Europe and Central Asia
2
Paraguay
2
Timor Leste/ East Timor
2
Romania
2
Guinea
1
Côte d’Ivoire / Ivory Coast
1
Morocco
1
Saudi Arabia
1
Jordan
1
Lebanon
1
Gambia
1
Papua New Guinea
1
Central African Republic
1
Peru
1
North Macedonia
1
El Salvador
1
Bolivia
1
Greece
1
Chile
1
Fiji
1
Solomon Islands
1
North Korea
1
Laos
1
Iran
1
North America
1
Denmark
1
Tunisia
1
United Kingdom
1
Authors & Publishers
Publication Years
Category
Countries
716
Clinical Guidelines
283
Public Health
83
Women & Child Health
69
Capacity Building
42
Pharmacy & Technologies
18
Key Resources
16
Toolboxes
TB
374
HIV
352
AMR
77
NTDs
72
Pharmacy
60
Mental Health
46
COVID-19
45
NCDs
45
Ebola
29
Refugee
23
Caregiver
21
Conflict
16
Rapid Response
15
Polio
11
Disability
9
Health Financing Toolbox
5
Natural Hazards
4
Specific Hazards
4
Planetary Health
4
Cholera
3
Global Health Education
3
Social Ethics
3
Zika
1
Patients with retreatment tuberculosis (TB) represent those
who have been treated previously for onemonth ormorewith
anti-TB drugs and who have been diagnosed once again with
the disease.These patientsmainly include relapses, treatment
after failure, or loss to follow-up on a first-line treatmen...
Tuberculosis treatment failure results in increased risk of morbidity, drug resistance, transmission and mortality. There are few data about tuberculosis treatment outcomes in Burkina Faso. The current study investigated the factors associated with ...
We systematically reviewed Medline as well as the references of published review articles for relevant studies of adherence to multidrug treatment of both drug-susceptible and drug-resistant TB thro...
1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea...
Lymphatic filariasis is a neglected tropical disease that can cause permanent disability through disruption of the lymphatic system. This disease is caused by parasitic filarial worms that are transmitted by mosquitos. Mass drug administration (MDA)...
The 7th edition of the Orange Guide provides practical guidance to health workers on the front line of TB control. It includes sections on HIV, MDR-TB and a review of the recommended treatment regimens
This guide is a resource for physicians and other health care professionals who provide care and treatment to patients with drug-resistant tuberculosis.
Version 10.1_5 October 2020
These Guidelines are available in different formats: As a paper booklet, a PDF, a mobile app, and now also as a website.
The 2019 version of the Guidelines introduces a new drug-... interaction panel and now consists of six main sections, including a general overview table of all major issues in PLWH, recommendations on antiretroviral treatment, drug-drug interactions, diagnosis, monitoring and treatment of co-morbidities, co-infections and opportunistic diseases.
Available in English, French, Spanish, German, Portuguese, Russian, Chinese and Japanese
The WHO South-East Asia (SEA) Region bears a high burden of tuberculosis (TB) and MDR-TB. In 2015, the Region accounted for nearly 200 000 or 35% of the global estimated new RR/MDR-TB cases eligible for treatment. Extensively drug-resis...
Following the encouraging initial results of the pilot project, the Ministry of Health is committed to increasing access to MDR-TB diagnosis, treatment and care. An expansion plan for the programmatic management of drug-resistant TB has been develop...
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International ... Monitoring. This text was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring.
The Updated guidelines on Management of tuberculosis in children and adolescents include new recommendations that cover diagnostic approaches for TB, shorter treatment for children with non-severe drug-susceptible TB, a new option for the treatment ...
This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is
a key component of leprosy treatment, as it is vital to prevent the progression of the infection.
Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with
the ...
The purpose of this manual is to define a limited number of indicators that will objectively describe the management and use of antimicrobials in hospitals and to provide tools and step-by-step instructions for designing and carrying out an assessment of antibiotic use and management in hospitals. T...
This manual summarizes key issues related to the safety of NTD medicines and their administration, with a focus on essential medicines used in mass drug administration (MDA), also called preventive chemotherapy. It can be used as a standalone refere...
Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are
estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co...
The objectives of these WHO guidelines are to provide updated evidence- based recommendations for the treatment of persons with hepatitis C infection using, where possible, all DAA-only combinations. The guidelines also provide recommendations on the preferred ... based on a patient’s HCV genotype and clinical history, and assess the appropriateness of continued use of certain medicines. This document also includes existing recommendations on screening for HCV infection and care of persons infected with HCV that were first issued in 2014
WHO Guidelines for malaria
recommended
25 Nov 2022
The WHO Guidelines for malaria bring together the Organization’s most up-to-date recommendations for malaria in one user-friendly and easy-to-navigate online platform.
The WHO Guidelines for malaria supersedes 2 previous WHO publications: the Guidelines for the treatment of mala...
Cryptococcal disease is one of the most common opportunistic infections among people living with advanced HIV disease and is a major contributor to severe illness, morbidity, and mortality, particularly in sub-Saharan Africa.
These guidelines update the recommendations that were first released i...
The main objective of these guidelines is to provide guidance on up-to-date, uniform, evidence-informed practices for suspecting, diagnosing and managing various forms of extra-pulmonary tuberculosis (EPTB) at all levels of healthcare delivery. They can then contribute to the National Programme to i...
